Exhibit 4.15 LICENSE AND OPTION AGREEMENT ---------------------------- This License and Option Agreement (the "Agreement") effective as of December 19, 2001 by and between ILEX Oncology, Inc., a Delaware corporation having its principal place of...License Agreement • April 26th, 2002 • Cardiome Pharma Corp • Pharmaceutical preparations • Delaware
AMONGMerger Agreement • April 26th, 2002 • Cardiome Pharma Corp • Pharmaceutical preparations
Exhibit 4.13 AGENCY AGREEMENT ---------------- February 28, 2002 Cardiome Pharma Corp. 3650 Wesbrook Mall Vancouver, B.C. V6S 2L2 Attention: Bob Rieder, President and Chief Executive Officer ------------------------------------------------------------...Agency Agreement • April 26th, 2002 • Cardiome Pharma Corp • Pharmaceutical preparations • British Columbia
CORREVIO PHARMA CORP. Common Shares Controlled Equity OfferingSM Sales AgreementSales Agreement • March 14th, 2019 • Correvio Pharma Corp. • Pharmaceutical preparations • New York
Correvio Pharma Corp., a corporation formed under the Canada Business Corporations Act (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follows:
BETWEENLicense Agreement • April 26th, 2002 • Cardiome Pharma Corp • Pharmaceutical preparations • Maryland
Exhibit 4.9 Page 1 EMPLOYMENT AGREEMENT This agreement is made as of the 5th of June 2001. Between: DR. ALAN EZRIN, 110 Quintas Lane, Moraga, California, 94556 (the "Employee") and CARDIOME PHARMA CORP., a corporation incorporated under the laws of...Employment Agreement • April 26th, 2002 • Cardiome Pharma Corp • Pharmaceutical preparations • British Columbia
Common Shares (Without Par Value)Underwriting Agreement • March 17th, 2005 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
ARTICLE 1 DEFINITIONSCollaborative Research and License Agreement • April 26th, 2002 • Cardiome Pharma Corp • Pharmaceutical preparations • Quebec
At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • February 18th, 2014 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
Cardiome Pharma Corp. (the “Company”), a corporation formed under the Canada Business Corporations Act (the “CBCA”), confirms its agreement (this “Agreement”) with MLV & Co. LLC (“MLV”), as follows:
UNDERWRITING AGREEMENTUnderwriting Agreement • July 29th, 2015 • Cardiome Pharma Corp • Pharmaceutical preparations • British Columbia
SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT dated as of May 15, 2018 between CORREVIO PHARMA CORP. as Borrower, The Subsidiary Guarantors from Time to Time Party Hereto, The Lenders from Time to Time Party Hereto, and CRG SERVICING LLC as...Term Loan Agreement • July 12th, 2018 • Correvio Pharma Corp. • Pharmaceutical preparations • New York
SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT, dated as of May 15, 2018 (this “Agreement”), among CORREVIO PHARMA CORP., a corporation incorporated pursuant to the federal laws of Canada (“Borrower”), the Subsidiary Guarantors from time to time party hereto, the Lenders from time to time party hereto and CRG SERVICING LLC, a Delaware limited liability company (“CRG Servicing”), as administrative and collateral agent for the Lenders (in such capacities, together with its successors and assigns, “Administrative Agent”).
COMMON SHARES CORREVIO PHARMA CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • August 2nd, 2019 • Correvio Pharma Corp. • Pharmaceutical preparations • New York
PURCHASE AGREEMENTPurchase Agreement • January 12th, 2016 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
PURCHASE AGREEMENT (the “Agreement”), dated as of January 12, 2016, by and between CARDIOME PHARMA CORP., a company incorporated under the Canada Business Corporations Act (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
TRANSITION AGREEMENTTransition Agreement • May 22nd, 2013 • Cardiome Pharma Corp • Pharmaceutical preparations
This Transition Agreement (the “Agreement”) is made and entered into as of April 25, 2013 (the “Effective Date”) by and between CARDIOME PHARMA CORP., a Canadian corporation with offices at 6190 Agronomy Rd., Suite 405, Vancouver, B.C., Canada, V6T 1Z3 ("Cardiome"), MERCK SHARP & DOHME (SWITZERLAND) GMBH, a company organized under the laws of Switzerland with offices at Rue de Lausanne 27, Sion, 1950, Switzerland (“MSD Switzerland”) and MERCK SHARP & DOHME CORP. (as successor-in-interest to the entity formerly known as Merck & Co., Inc.), a corporation organized under the laws of New Jersey with offices at One Merck Drive, Whitehouse Station, NJ 08889-0100, U.S.A. (“MSD Corp.” and, together with MSD Switzerland, “Merck”). Cardiome, MSD Switzerland and MSD Corp. are each referred to from time to time herein either individually as a “Party” or collectively as the “Parties”.
This Employment Agreement (the "Agreement") is made as of March 8, 2002,Employment Agreement • May 8th, 2003 • Cardiome Pharma Corp • Pharmaceutical preparations • British Columbia
CARDIOME PHARMA CORP., a corporation incorporated under the laws of Canada and having its head office at 3650 Wesbrook Mall, Vancouver, British Columbia, V6S 2L2
CIPHER PHARMACEUTICALS INC. and CARDIOME PHARMA CORP. and CORREVIO PHARMA CORP. ARRANGEMENT AGREEMENT March 19, 2018Arrangement Agreement • July 12th, 2018 • Correvio Pharma Corp. • Pharmaceutical preparations • British Columbia
Arrangement Agreement dated March 19, 2018 among Cipher Pharmaceuticals Inc. (“Cipher”), Cardiome Pharma Corp. (“Cardiome”) and Correvio Pharma Corp. (“Correvio”).
LICENSE AGREEMENT Dated as of May 5, 2016 by and between DURATA THERAPEUTICS INTERNATIONAL B.V. and CORREVIO INTERNATIONAL SÁRLLicense Agreement • July 12th, 2018 • Correvio Pharma Corp. • Pharmaceutical preparations • New York
This License Agreement (this "Agreement"), effective as of May 5, 2016 (the "Effective Date"), is made by and between Durata Therapeutics International B.V., a private limited company registered in the Netherlands with offices at Barbara Strozzilaan 101, Spaces Zuida, Amsterdam, the Netherlands ("Allergan"), and Correvio International Sárl, a Swiss corporation with offices at Rue des Alpes 21, Case postale 1674, 1201 Geneva, Switzerland ("Licensee"). Each of Allergan and Licensee is referred to herein individually as a "Party" and collectively as the "Parties." Certain capitalized terms have the meanings provided in Article I below.
ARRANGEMENT AGREEMENT March 15, 2020Arrangement Agreement • March 23rd, 2020 • Correvio Pharma Corp. • Pharmaceutical preparations • British Columbia
Arrangement Agreement dated March 15, 2020 among ADVANZ PHARMA Corp. Limited (“Parent”), Mercury Pharma Group Limited (“Purchaser”) and Correvio Pharma Corp. (“Correvio”).
AMENDED AND RESTATED TERM LOAN AGREEMENT dated as of May 11, 2017 between CARDIOME PHARMA CORP. as Borrower, The Subsidiary Guarantors from Time to Time Party Hereto, The Lenders from Time to Time Party Hereto, and CRG SERVICING LLC as Administrative...Term Loan Agreement • May 22nd, 2017 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
AMENDED AND RESTATED TERM LOAN AGREEMENT, dated as of May 11, 2017 (this “Agreement”), among CARDIOME PHARMA CORP., a corporation incorporated pursuant to the federal laws of Canada (“Borrower”), the Subsidiary Guarantors from time to time party hereto, the Lenders from time to time party hereto and CRG SERVICING LLC, a Delaware limited liability company (“CRG Servicing”), as administrative and collateral agent for the Lenders (in such capacities, together with its successors and assigns, “Administrative Agent”).
FORM OF SUBSCRIPTION AGREEMENT FOR SPECIAL WARRANTSSubscription Agreement • February 17th, 2006 • Cardiome Pharma Corp • Pharmaceutical preparations • British Columbia
The undersigned subscriber (the “Subscriber”) hereby irrevocably subscribes for special warrants (the “Special Warrants”) of Cardiome Pharma Corp. (the “Corporation”) for an aggregate subscription price of $ (the “Subscription Price”), representing a subscription price of $7.2387 per Special Warrant, on the terms and conditions set forth in this Agreement (the “Subscription Agreement”). The Subscription Agreement is being entered into pursuant to a letter agreement (the “Letter Agreement”) dated August 29, 2005 between the Corporation and the Subscriber, among others.
SUPPLY AGREEMENT Dated as of May 5, 2016 by and between DURATA THERAPEUTICS INTERNATIONAL B.V. and CORREVIO INTERNATIONAL Sárl SUPPLY AGREEMENTSupply Agreement • May 17th, 2016 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
This Supply Agreement (this “Agreement”), dated as of May 5, 2016 (the “Effective Date”), is made by and between Correvio International Sárl, a Swiss corporation with offices at Rue des Alpes 21, Case postale 1674, 1201 Geneva, Switzerland (“Licensee”), and Durata Therapeutics International B.V., a company registered in the Netherlands with offices at Spaces Zuidas II, Barbara Strozzilaan 101, 1083 HN Amsterdam, the Netherlands (“Allergan”). Each of Licensee and Allergan is referred to herein individually as a “Party” and collectively as the “Parties.” Certain capitalized terms have the meanings provided in Article I below.
Amended and Restated At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • March 7th, 2016 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
Cardiome Pharma Corp. (the “Company”), a corporation formed under the Canada Business Corporations Act (the “CBCA”), confirms its agreement (this “Agreement”) with FBR Capital Markets & Co. (“FBR”) and MLV & Co. LLC (“MLV”, each of FBR and MLV, individually a “Distribution Agent”, and collectively, the “Distribution Agents”), to amend and restate the At Market Issuance Sales Agreement dated February 18, 2014 between the Company and MLV, as follows:
COMMON SHARES CARDIOME PHARMA CORP. UNDERWRITING AGREEMENTUnderwriting Agreement • July 26th, 2016 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
Cardiome Pharma Corp., a corporation organized and existing under the laws of Canada (the “Company”), proposes to issue and sell, subject to the terms and conditions stated herein, to the several underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of 10,000,000 common shares (the “Firm Shares”), without par value. In addition, for the sole purpose of covering over-allotments in connection with the sale of the Firm Shares, at the option of the Underwriters, the Company grants to the Underwriters the option to purchase up to an additional 1,500,000 common shares (the “Additional Shares” and, together with the Firm Shares, the “Shares”). Leerink Partners LLC (“Leerink”) is acting as the sole bookrunner and the representative of the Underwriters in connection with the offering and sale of the Shares contemplated herein (the “Offering”).
Exclusive License and Supply Agreement by and between Cardiome Pharma Corp. and Correvio International Sárl and SteadyMed Ltd.Exclusive License and Supply Agreement • July 12th, 2018 • Correvio Pharma Corp. • Pharmaceutical preparations • New York
This Exclusive License and Supply Agreement (this “Agreement”) is made as of 28th June 2015 (the “Effective Date”), by and between Cardiome Pharma Corp., a company duly incorporated under the laws of Canada, with its principal place of business at 1441 Creekside Drive, 6th Floor, Vancouver BC V6J 4S7 and Correvio International Sàrl, a company duly incorporated and existing under the laws of Switzerland, with its principal place of business at Rue des Alpes 21, 1201 Geneva, Switzerland (hereinafter collectively referred to as “Cardiome”), and SteadyMed Ltd., a company organized and existing under the laws of Israel with its principal place of business at 5 Oppenheimer Street, Rehovot 7670105, Israel (“SteadyMed”). Each of Cardiome and SteadyMed is referred to individually as a “Party” and collectively as the “Parties”.
EXECUTION VERSIONSettlement Agreement • March 4th, 2013 • Cardiome Pharma Corp • Pharmaceutical preparations
This Settlement Agreement (this “Settlement Agreement”) is entered into as of December 10, 2012 (the “Settlement Date”), by and among Cardiome Pharma Corp., a Canadian corporation with offices at 6190 Agronomy Rd., Suite 405, Vancouver, B.C., Canada, V6T 1Z3 (“CARDIOME”), and Merck Sharp & Dohme Corp. (as successor in interest to the entity formerly known as Merck & Co., Inc.), a corporation organized under the laws of New Jersey with offices at One Merck Drive, Whitehouse Station, NJ 08889-0100, U.S.A. (“Merck & Co.”).
DISTRIBUTION AGREEMENT BETWEEN CORREVIO INTERNATIONAL SARL AND BASILEA PHARMACEUTICA INTERNATIONAL LTD. Dated as of September 11, 2017Distribution Agreement • September 25th, 2017 • Cardiome Pharma Corp • Pharmaceutical preparations
THIS DISTRIBUTION AGREEMENT dated as of September 11, 2017 (the “Effective Date”) is made by and between Correvio International Sàrl, a corporation organized and existing under the laws of Switzerland with offices at Rue des Alpes 21, Case postale 1674, 1201 Geneva, Switzerland (hereinafter “Cardiome”), and Basilea Pharmaceutica International Ltd., a corporation organized and existing under the laws of Switzerland, with offices at Grenzacherstrasse 487, CH-4058, Basel, Switzerland (hereinafter “Basilea”). Cardiome and Basilea may be referred to herein individually as a “Party” or collectively as the “Parties.” WITNESSETH:
This Employment Agreement (the "Agreement") is made as of March 1, 2003,Employment Agreement • May 8th, 2003 • Cardiome Pharma Corp • Pharmaceutical preparations • British Columbia
CARDIOME, INC., a corporation incorporated under the laws of Delaware and having its registered office at Suite 1113, 11th Floor, 1111 Brickell Avenue, Miami, Florida 33131 USA
DEVELOPMENT AND TRANSFER AGREEMENTDevelopment and Transfer Agreement • May 8th, 2003 • Cardiome Pharma Corp • Pharmaceutical preparations • Fribourg
CARDIOME Pharma Corp., a corporation incorporated under the laws of Canada, with an office at 3650 Wesbrook Mall, Vancouver, B.C. V6S 2L2, Canada ("CARDIOME")
LICENSE AGREEMENT Dated as of May 5, 2016 by and between DURATA THERAPEUTICS INTERNATIONAL B.V. andLicense Agreement • May 17th, 2016 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
This License Agreement (this “Agreement”), effective as of May 5, 2016 (the “Effective Date”), is made by and between Durata Therapeutics International B.V., a private limited company registered in the Netherlands with offices at Barbara Strozzilaan 101, Spaces Zuida, Amsterdam, the Netherlands (“Allergan”), and Correvio International Sárl, a Swiss corporation with offices at Rue des Alpes 21, Case postale 1674, 1201 Geneva, Switzerland (“Licensee”). Each of Allergan and Licensee is referred to herein individually as a “Party” and collectively as the “Parties.” Certain capitalized terms have the meanings provided in Article I below.
DEVELOPMENT AND LICENSE AGREEMENT BETWEEN CARDIOME DEVELOPMENT LTD. AND ELI LILLY AND COMPANY SIGNED AS OF APRIL 30, 2007Development and License Agreement • March 28th, 2008 • Cardiome Pharma Corp • Pharmaceutical preparations
This DEVELOPMENT AND LICENSE AGREEMENT (the “Agreement”) is entered into as of April 30, 2007, by and between Eli Lilly and Company, a corporation, incorporated under the laws of the State of Indiana, having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana USA, 46285, and its Affiliates (hereinafter collectively referred to as “Lilly”), and Cardiome Development Ltd., a corporation incorporated under the laws of British Columbia, Canada, having its principal place of business at 6190 Agronomy Drive, 6th Floor, Vancouver, B.C., Canada, V6T 1Z3, (“Cardiome”). Lilly and Cardiome shall sometimes hereinafter be individually referred to as a “Party” and collectively referred to as the “Parties”). The Parties agree as follows:
FIRST AMENDING AGREEMENT TO AMENDED AND RESTATED TERM LOAN AGREEMENTTerm Loan Agreement • April 9th, 2018 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
FIRST AMENDING AGREEMENT TO THE AMENDED AND RESTATED TERM LOAN AGREEMENT, dated as of March 27, 2018 (this “Amending Agreement”) among Cardiome Pharma Corp., as Borrower, the Subsidiary Guarantors party hereto, the Lenders party hereto and CRG Servicing LLC, as Administrative Agent.
CREDIT, SECURITY AND GUARANTY AGREEMENTCredit, Security and Guaranty Agreement • July 29th, 2014 • Cardiome Pharma Corp • Pharmaceutical preparations
THIS CREDIT, SECURITY AND GUARANTY AGREEMENT (this “Agreement”), dated as of July 18, 2014 (the “Closing Date”) by and among MIDCAP FUNDING V, LLC, a Delaware limited liability company (“MidCap”), as administrative agent (“Agent”), the Lenders listed on the Credit Facility Schedule attached hereto and otherwise party hereto from time to time (each a “Lender”, and collectively the “Lenders”), and CARDIOME PHARMA CORP., an amalgamated corporation validly existing under the Canada Business Corporations Act and extraprovincially registered in the Province of British Columbia (“Parent”), and the other entities shown as signatories hereto as a Borrower (together with Parent, collectively in the singular, “Borrower”), provides the terms on which Lenders agree to lend to Borrower and Borrower shall repay Lenders. The parties agree as follows:
FIRST AMENDING AGREEMENT TO TERM LOAN AGREEMENTTerm Loan Agreement • February 27th, 2017 • Cardiome Pharma Corp • Pharmaceutical preparations • New York
FIRST AMENDING AGREEMENT TO TERM LOAN AGREEMENT dated as of February 17, 2017 (this “Amending Agreement”) among Cardiome Pharma Corp., as Borrower (the “Borrower” and, together with the Subsidiary Guarantors, the “Obligors”), the Subsidiary Guarantors, CRG Servicing LLC, as administrative and collateral agent (the “Agent”), and the Lenders.
FOURTH AMENDING AGREEMENT TO SECOND AMENDED AND RESTATED TERM LOAN AGREEMENTTerm Loan Agreement • April 30th, 2020 • Correvio Pharma Corp. • Pharmaceutical preparations • New York
FOURTH AMENDING AGREEMENT TO THE SECOND AMENDED AND RESTATED TERM LOAN AGREEMENT, dated as of March 12, 2020 (this “Amending Agreement”) among Correvio Pharma Corp., as Borrower, the Subsidiary Guarantors party hereto, the Lenders party hereto and CRG Servicing LLC, as Administrative Agent.
AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 28th, 2008 • Cardiome Pharma Corp • Pharmaceutical preparations
This Amendment, effective July ___, 2006, (this “Amendment”) is made by and between Cardiome Pharma Corp., a Canadian corporation having its offices at 3650 Wesbrook Mall, Vancouver, BC, Canada V6S 2L2 and Cardiome Research and Development (Barbados) Inc. (collectively, “Cardiome”), and Astellas US LLC, a Delaware limited liability company having its principal place of business at Three Parkway North, Deerfield, IL, USA 60015-2548 (“Astellas”), a successor to Fujisawa Healthcare, Inc.
